TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.
a lot of people have counted on his loyalty have found themselves in pinstripes or close to them. harry litman, bryan jacobs, thanks very much for your expertise. okay, next up, michael cohen is here to tell us how the former president gets staffers to do his bidding. he doesn t give you questions. he doesn t give you orders. he speaks in a code. nking. i ll be e taking meetings with family and friends. and checking voicemail as my activities permit. i ll connect with you after reconnecting with me. get 1.9% apr for 36 months plus $1,500 purchase allowance on a 2023 xt5 and xt6 when you finance through cadillac financial. having triplets is. -amazing -expensive. so, we switched to the bargain detergent, but we ended up using three times as much so we re back with tide, and the clothes are clean again.
Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.